BNP Paribas Financial Markets Increases Stake in Vera Therapeutics, Inc. $VERA

BNP Paribas Financial Markets lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 86.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 474,668 shares of the company’s stock after acquiring an additional 220,692 shares during the period. BNP Paribas Financial Markets owned 0.74% of Vera Therapeutics worth $24,037,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the period. Optimize Financial Inc raised its holdings in Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares during the period. Intech Investment Management LLC raised its holdings in Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after buying an additional 424 shares during the period. Invesco Ltd. raised its holdings in Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after buying an additional 550 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after buying an additional 639 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00. Following the completion of the sale, the chief executive officer owned 216,744 shares of the company’s stock, valued at approximately $7,963,174.56. This trade represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Stock Down 3.3%

Shares of NASDAQ:VERA opened at $32.29 on Friday. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 52-week low of $19.07 and a 52-week high of $56.05. The company has a 50 day moving average of $37.71 and a two-hundred day moving average of $41.24. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -5.83 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the business earned ($0.81) EPS. As a group, analysts forecast that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a report on Wednesday, March 11th. Evercore set a $91.00 price target on shares of Vera Therapeutics in a report on Friday, May 15th. The Goldman Sachs Group restated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday. Finally, William Blair restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.